CHS is a cutting-edge AI-driven diagnostics startup committed to providing radiologists and other healthcare professionals with state-of-the-art solutions. Our products raise the bar for patient outcomes by bridging the gap between accurate diagnosis and value-driven care.
Mission
CHS technology innovations will enable the healthcare industry to increase the scales of proactive, predictive diagnosis through virtualization at reduced cost of operations and alleviation of capacity gaps at healthcare providers.
Vision
CHS aims to become a global leader in providing innovative cognitive AI and Virtual Reality based technology products to enable the healthcare industry to provide proactive, affordable care and universal healthcare access to all global citizens.
Our journey has been characterized by innovation, dedication, and a steadfast pursuit of excellence in the field of healthcare.
-
2017
Incorporated in India
-
2018
Early prototype released
Selected to ET's Go Global Initiative
Global Entity setup in Singapore -
2019
1st Seed Investment
Release of Charybdis
Medical papers (co-authored)
Release of Choco for COVID-19
CDSCO approvals -
2022
Additional Seed investments
Multi-modal Choco releases
Field testing in hospitals, airport, and tuk-tuk -
2023 H1
Patent grant for Choco
Scylla prototype -
2023 H2
1st Paid Project (Meghalaya, NHM)
ICMR collaboration Project kickoff -
2024
NHM & CSR projects (paid)
Scylla Early Adopter program
Hiring and managing "S-Curve" -
2025- 2028
Private medical institutions
Medical colleges
Overseas expansion
Additional funding, IPO
3C – Gee Gee Emerald
#312, Nungambakkam High Road
Nungambakkam
Chennai – 600 034, Tamilnadu, INDIA.
3 CHURCH STREET,
#29-01, SAMSUNG HUB,
SINGAPORE 049483